Download PDF
Thromb Haemost 1999; 81(01): 87-95
DOI: 10.1055/s-0037-1614424
Review Article
Schattauer GmbH

β2-Glycoprotein I Is Proteolytically Cleaved In Vivo upon Activation of Fibrinolysis

Daniëlle A. Horbach
1   From the Departments of Haematology and, Utrecht University, The Netherlands
2   From the Departments of Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands and the, Utrecht University, The Netherlands
3   From the Departments of Institute of Biomembranes, Utrecht University, The Netherlands
,
Erica van Oort
1   From the Departments of Haematology and, Utrecht University, The Netherlands
2   From the Departments of Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands and the, Utrecht University, The Netherlands
,
Ton Lisman
1   From the Departments of Haematology and, Utrecht University, The Netherlands
,
Joost C. M. Meijers
1   From the Departments of Haematology and, Utrecht University, The Netherlands
3   From the Departments of Institute of Biomembranes, Utrecht University, The Netherlands
,
Ronald H. W. M. Derksen
2   From the Departments of Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands and the, Utrecht University, The Netherlands
,
Philip G. de Groot
1   From the Departments of Haematology and, Utrecht University, The Netherlands
3   From the Departments of Institute of Biomembranes, Utrecht University, The Netherlands
› Author Affiliations
Further Information

Publication History

Received13 July 1998

Accepted after revision10 September 1998

Publication Date:
08 December 2017 (online)

   Permissions and Reprints

Summary

β2-glycoprotein I (β2GPI) is a plasma glycoprotein with unknown physiological function(s). In in vitro experiments it has been demonstrated that β2GPI has both anticoagulant properties, such as the inhibition of factor X and prothrombin activation and procoagulant properties, such as the inhibition of the anticoagulant activity of activated protein C. Besides this, β2GPI bound to cardiolipin is recognized by anti-phospholipid antibodies (aPL).

In this study we demonstrate that β2GPI is very sensitive for cleavage between Lys317 and Thr318 by plasmin, resulting in two immunologically different cleaved forms. In vitro experiments show that these plasmin cleaved forms of β2GPI bind to negatively charged phospho-lipids with much lower affinity compared to intact β2GPI. Similar to plasmin, trypsin and elastase can also induce this proteolytical cleavage in β2GPI, whereas thrombin and factor Xa do not cleave β2GPI. The in vivo occurrence of the proteolytical cleavage was demonstrated by the finding that in plasmas of patients with disseminated intravascular coagulation(DIC) and in plasmas of patients treated with streptokinase, significant amounts of cleaved β2GPI (up to 12 μg/ml) are present.

During the development of DIC, the increase in levels of cleaved β2GPI is accompanied by a 70% decrease in the levels of intact β2GPI, whereas in streptokinase treated patients levels of intact β2GPI stay within the normal range.

This study demonstrates for the first time that during in vivo activation of fibrinolysis β2GPI is cleaved, which results in the formation of a form of β2GPI with much lower affinity for negatively charged phospholipids. Plasmin is most likely responsible for this modification.

 

  • References

  • 1 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98.
    CrossrefPubMedGoogle Scholar
  • 2 Harris EN, Asherson RA, Hughes GR. Antiphospholipid antibodieS-auto-antibodies with a difference. Annu Rev Med 1988; 39: 261-71.
    CrossrefPubMedGoogle Scholar
  • 3 Horbach DA, Van Oort E, Donders RCJM, Derksen RHWM, De Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus – Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-24.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoanti-bodies. Blood 1994; 84: 2854-67.
    PubMedGoogle Scholar
  • 5 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
    CrossrefPubMedGoogle Scholar
  • 7 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein factor. Lancet 1990; 335: 1544-7.
    CrossrefPubMedGoogle Scholar
  • 8 Oosting JD, Derksen RHWM, Entjes I HT, Bouma BN, De Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemost 1992; 67: 499-502.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma β2-glycoprotein. Proc Natl Acad Sci USA 1984; 81: 3640-4.
    CrossrefPubMedGoogle Scholar
  • 10 Steinkasserer A, Barlow PN, Willis AC, Kertesz Z, Campbell ID, Sim RB, Norman DG. Activity, disulphide mapping and structural modelling of the fifth domain of human β2-glycoprotein I. FEBS Lett 1992; 313: 193-7.
    CrossrefPubMedGoogle Scholar
  • 11 Kato H, Enjyoji K. Amino acid sequence and location of the disulfide bonds in bovine β2-glycoprotein I: the presence of five sushi domains. Biochemistry 1991; 30: 11687-94.
    CrossrefPubMedGoogle Scholar
  • 12 Polz E, Wurm H, Kostner GM. Investigations on β2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem 1980; 11: 265-70.
    CrossrefPubMedGoogle Scholar
  • 13 Polz E, Kostner GM. The binding of β2-glycoprotein-I to human serum lipoproteins: distribution among density fractions. FEBS Lett 1979; 102: 183-6.
    CrossrefPubMedGoogle Scholar
  • 14 Nimpf J, Wurm H, Kostner GM. Interaction of β2-glycoprotein-I with human blood platelets: influence upon the ADP-induced aggregation. Thromb Haemost 1985; 54: 397-401.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Wurm H. β2-glycoprotein-I (apolipoprotein H) interactions with phospho-lipid vesicles. Int J Biochem 1984; 16: 511-5.
    CrossrefPubMedGoogle Scholar
  • 16 Schousboe I. Binding of β2-glycoprotein I to platelets: effect of adenylate cyclase activity. Thromb Res 1980; 19: 225-37.
    CrossrefPubMedGoogle Scholar
  • 17 Schousboe I. β2-glycoproteine I: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-91.
    PubMedGoogle Scholar
  • 18 Schousboe I, Rasmussen MS. Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by β2-glycoprotein I and anti-β2-glycoprotein I. Thromb Haemost 1995; 73: 798-804.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 McNally T, Mackie IJ, Isenberg DA, Machin SJ. β2-glycoprotein-I inhibits factor XII activation on triglyceride rich lipoproteins: The effect of antibodies from plasma of patients with antiphospholipid syndrome. Thromb Haemost 1996; 76: 220-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Goldsmith GH, Pierangeli SS, Branch DW, Gharavi AE, Harris EN. Inhibition of prothrombin activation by antiphospholipid antibodies and β2-glycoprotein I. Br J Haematol 1994; 87: 548-54.
    CrossrefPubMedGoogle Scholar
  • 21 Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993; 70: 342-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, Zwaal RFA. Prothrombinase activity of human platelets is inhibited by β2-glyco-protein-I. Biochim Biophys Acta Gen Subj 1986; 884: 142-9.
    CrossrefPubMedGoogle Scholar
  • 23 Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. β2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospho-lipid surface. Thromb Haemost 1996; 75: 49-55.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Matsuda J, Gohchi K, Kawasugi K, Gotoh M, Saitoh N, Tsukamoto M. Inhibitory activity of anti-β2-glycoprotein I antibody on factor Va degradation by activated-protein C and its cofactor protein S. Am J Hematol 1995; 49: 89-91.
    CrossrefPubMedGoogle Scholar
  • 25 Bancsi LF, van der Linden IK, Bertina RM. β2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992; 67: 649-53.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP. et al Inherited thrombophilia: part 1. Thromb Haemost 1996; 76: 651-62.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use innovative therapies in sepsis. Chest 1992; 101: 1644-55.
    CrossrefPubMedGoogle Scholar
  • 28 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-6.
    CrossrefPubMedGoogle Scholar
  • 29 Lijnen HR, Van Hoef B, De Cock F, Okada K, Ueshima S, Matsuo O, Collen D. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991; 266: 11826-32.
    PubMedGoogle Scholar
  • 30 Hackeng TM, Hessing M, Van’t Veer C, Meijer-Huizinga F, Meijers JCM, De Groot PG, Van Mourik JA, Bouma BN. Protein S binding to human endothelial cells is required for expression of cofactor activity for activated protein C. J Biol Chem 1993; 268: 3993-4000.
    PubMedGoogle Scholar
  • 31 Bock PE, Craig PA, Olson ST, Singh P. Isolation of Human Blood Coagulation α-Factor Xa by Soybean Trypsin Inhibitor-Sepharose Chromatography and Its Active-Site Titration with Fluorescein Mono-p-guanidinobenzoate. Arch Biochem Biophys 1989; 273: 375-88.
    CrossrefPubMedGoogle Scholar
  • 32 De Kruif J, Terstappen L, Boel E, Logtenberg T. Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc Natl Acad Sci USA 1995; 92: 3938-42.
    CrossrefPubMedGoogle Scholar
  • 33 Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222: 581-97.
    CrossrefPubMedGoogle Scholar
  • 34 Brunner J, Skrabal P, Hauser H. Single bilayer vesicles prepared without sonication. Physio-chemical properties. Biochim Biophys Acta 1976; 455: 322-31.
    CrossrefPubMedGoogle Scholar
  • 35 Van Wijnen M, Stam JG, Van’t Veer C, Meijers JCM, Reitsma PH, Bertina RM, Bouma BN. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost 1996; 76: 397-403.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Rouser G, Fkeischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5: 494-6.
    CrossrefPubMedGoogle Scholar
  • 37 Hunt JE, Simpson RJ, Krilis SA. Identification of a region of β2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993; 90: 2141-5.
    CrossrefPubMedGoogle Scholar
  • 38 Chonn A, Semple SC, Cullis PR. β2-Glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of “non-self” particles. J Biol Chem 1995; 270: 25845-9.
    CrossrefPubMedGoogle Scholar
  • 39 Wurm H, Polz E, Holasek A, Kostner GM. Studies on the possible function of β2-glycoprotein I: influence in the triglyceride metabolism in the rat. Metabolism 1982; 31: 484-6.
    CrossrefPubMedGoogle Scholar
  • 40 Balasubramanian K, Chandra J, Schroit AJ. Immune clearance of phosphatidylserine-expressing cells by phagocytes. The role of β2-glycoprotein I in macrophage recognition. J Biol Chem 1997; 272: 31113-7.
    CrossrefPubMedGoogle Scholar
  • 41 Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-73.
    CrossrefPubMedGoogle Scholar
  • 42 Manfredi AA, Rovere P, Heltai S, Galati G, Nebbia G, Tincani A, Balestrieri G, Sabbadini MG. Apoptotic cell clearance in systemic lupus erythematosus – II. Role of β2-glycoprotein I. Arthritis Rheum 1998; 41: 215-23.
    CrossrefPubMedGoogle Scholar
  • 43 Ayala A, Urbanich MA, Herdon CD, Chaudry IH. Is sepsiS-induced apoptosis associated with macrophage dysfunction?. J Trauma 1996; 40: 568-73.
    CrossrefPubMedGoogle Scholar
  • 44 Ayala A, Herdon CD, Lehman DL, Ayala CA, Chaudry IH. Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Blood 1996; 87: 4261-75.
    PubMedGoogle Scholar
  • 45 Ayala A, Karr SM, Evans TA, Chaudry IH. Factors responsible for peritoneal granulocyte apoptosis during sepsis. J Surg Res 1997; 69: 67-75.
    CrossrefPubMedGoogle Scholar
  • 46 Williams TE, Ayala A, Chaudry IH. Inducible macrophage apoptosis following sepsis is mediated by cysteine protease activation and nitric oxide release. J Surg Res 1997; 70: 113-8.
    CrossrefPubMedGoogle Scholar
  • 47 Ohkura N, Hagihara Y, Yoshimura T, Goto Y, Kato H. Plasmin can reduce the function of human β2-glycoprotein I by cleaving domain V into a nicked form. Blood 1998; 91: 4173-9.
    PubMedGoogle Scholar